For the fourth straight year, Louis P. Kassa III, MPA, chief executive officer of the Hepatitis B Foundation, Baruch S. Blumberg Institute and Pennsylvania Biotechnology Center (PABC), has been chosen by the Philadelphia Business Journal for its 2026 Power 100 list, which can be found here.

Timothy M. Block, PhD, who founded the PABC and is on its Board of Directors, said: “Lou Kassa has become a recognized authority and influential Biotechnology leader. He has used that stature to advocate for the biotech industry and life sciences research across the country well beyond the Philadelphia region.”

The Philadelphia Business Journal noted that last year, Kassa was among the leading local voices in the life sciences industry speaking on the topic of the administration’s efforts to reduce NIH funding.

Louis P. Kassa III, MPA, is CEO of the Pennsylvania Biotechnology Center (PABC), Baruch S. Blumberg Institute and Hepatitis B Foundation, which he joined as EVP and COO in 2014. Kassa leads the PABC, home to the Hepatitis B Foundation and Baruch S. Blumberg Institute. He previously was State Director and COO at VisionQuest National Ltd., a national behavioral health company.

A Bucks County resident, Kassa was awarded an honorary Doctor of Humane Letters from Holy Family University in 2025. He earned an undergraduate degree at Penn State University and a Master of Public Administration from Villanova University. 

Kassa is a board member of numerous organizations: Bucks County Workforce Development Board, Central Bucks Chamber of Commerce, Startup Bucks, Yards Sciences, Bucks County Music Project, Family Foundations Partnership and Triumph in Recovery.

About the Pennsylvania Biotechnology Center (PABC): The PABC uses a highly successful services-based approach to nurture and guide its member companies to success, advance biotechnology and maximize synergies among nonprofit scientists and their commercial colleagues. The PABC has more than 90 member companies and organizations, mostly small to mid-size science, research and pharmaceutical companies. Nearly 50 of those companies operate on the Doylestown campus, which is home to the Hepatitis B Foundation and the Blumberg Institute. The PABC also manages B+labs at Cira Centre, an incubator in Philadelphia with 18 resident companies, in partnership with Brandywine Realty Trust. PABC companies have produced numerous FDA-approved drugs and medical devices, and a recent study found that the PABC’s economic impact exceeded $7.3 billion and created more than 1,100 new jobs during a recent six-year period. Please visit our website and follow us on LinkedIn, Instagram, Twitter (@BiotechnologyPa) and Facebook.

About the Hepatitis B Foundation – Our vision is a world free of hepatitis B and liver cancer. As the world’s leading hepatitis B advocacy and research organization, the Hepatitis B Foundation is one of the most active proponents of improving hepatitis B screening, prevention and treatment of the disease. We are the only nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy. Founded in 1991, the Hepatitis B Foundation is based in Doylestown, Pa., with staff in Philadelphia and Washington, D.C. For more, go to www.hepb.org, follow us on LinkedIn, Twitter, Instagram and Facebook (@hepbfoundation) or contact us through info@hepb.org or 215-489-4900.

About the Baruch S. Blumberg Institute: An independent, nonprofit research organization, the Blumberg Institute was launched in 2003 by the Hepatitis B Foundation to advance its research mission. Today, the Institute is a leading center for translational research in hepatitis B, liver cancer and related diseases. The Blumberg Institute operates in the Pennsylvania Biotechnology Center (PABC), which it manages, in Doylestown, Pa. The Institute also runs a state-of-the-art incubator in Philadelphia, B+labs at Cira Centre, which is a partnership with Brandywine Realty Trust. Visit our website and follow us on LinkedIn and X, @BlumbergInstit1.